

## Paclitaxel – weekly (breast)

### Indication

Palliative therapy for advanced breast cancer where initial chemotherapy with an anthracycline has failed or is inappropriate.

(NICE CG81)

### ICD-10 codes

Codes pre-fixed with C50.

### Regimen details

#### 21 day cycle

Day	Drug	Dose	Route
1, 8, 15	Paclitaxel	80*mg/m <sup>2</sup>	IV infusion

#### 28 day cycle

Day	Drug	Dose	Route
1, 8, 15	Paclitaxel	90*mg/m <sup>2</sup>	IV infusion

No treatment on day 22

Dose may vary from 60-100mg/m<sup>2</sup> based on performance status.

### Cycle frequency

21 or 28 days

### Number of cycles

6 cycles

### Administration

Paclitaxel is administered in a 250-500mL sodium chloride 0.9% non-PVC infusion bag with a 0.22 micron in-line filter over 1 hour.

Blood pressure and pulse should be monitored regularly (e.g. every 30 minutes) during paclitaxel infusion.

Patients should be observed closely for hypersensitivity reactions, particularly during the first and second infusions. Hypersensitivity reactions may occur within a few minutes following the initiation of the infusion of paclitaxel. Facilities for the treatment of hypotension and bronchospasm **must** be available.

If hypersensitivity reactions occur, minor symptoms such as flushing or localised cutaneous reactions do not require discontinuation of therapy. The infusion may be temporarily interrupted and when symptoms improve restarted at a slower infusion rate. Chlorphenamine 10mg IV may be administered. Severe reactions, such as hypotension, bronchospasm or generalised rash/erythema require immediate discontinuation of paclitaxel and appropriate therapy should be initiated.

### Pre-medication

30 minutes prior to each infusion:

Chlorphenamine 10mg IV slow bolus

Dexamethasone 8mg IV slow bolus

## Emetogenicity

This regimen has moderate emetic potential.

## Additional supportive medication

Mouthwashes as per local policy

H<sub>2</sub> antagonist or PPI, if required, as per local policy

## Extravasation

Paclitaxel – vesicant (Group5)

## Investigations – pre first cycle

Investigation	Validity period (or as per local practice)
FBC	14 days
U+E (including creatinine)	14 days
LFTs	14 days

## Investigations – pre subsequent cycles

Investigation	Validity period (or as per local practice)
FBC	24 hours – prior to each dose
U+E (including creatinine)	72 hours – prior to day 1 only
LFTs	72 hours – prior to day 1 only

## Standard limits for administration to go ahead

If blood results not within range, authorisation to administer **must** be given by prescriber/ consultant

Investigation	Limit
Neutrophils	$\geq 1.0 \times 10^9/L$
Platelets	$\geq 100 \times 10^9/L$
Bilirubin	$< 1.5 \times ULN$
AST/ALT	$< 5 \times ULN$

## Dose modifications

### • Haematological toxicity

If neutrophils  $< 1.0 \times 10^9/L$  and/or platelets  $< 100 \times 10^9/L$  delay for 1 week then resume at 100% dose. If delayed for  $> 1$  week discuss with consultant.

In the case of febrile neutropenia (neutrophils  $< 0.5 \times 10^9/L$  and fever  $> 38.5^\circ C$  requiring IV antibiotics) reduce paclitaxel to  $60mg/m^2$  for all future doses.

### • Renal impairment

No dose modifications required.

### • Hepatic impairment

Paclitaxel is not recommended in severe hepatic impairment. If bilirubin  $< 1.5 \times ULN$  and AST/ALT  $< 5 \times ULN$  proceed with 100% dose. For more severe hepatic impairment, treatment may only proceed on consultant's decision, at a reduced dose with weekly monitoring of LFTs.

- **Other toxicities**

Toxicity	Definition	Paclitaxel dose
Neuropathy	Grade 2	Reduce to a maximum of 70mg/m <sup>2</sup> for all subsequent doses.
	Grade ≥ 3	Discontinue

For all other grade ≥ 2 toxicities (except alopecia) withhold until grade ≤ 1 and continue with 70mg/m<sup>2</sup> dose. If delayed for > 1 week, discuss with consultant.

For any grade 4 toxicity (except alopecia) withhold and discuss with consultant.

**Adverse effects** - for full details consult product literature/ reference texts

- **Rare or serious side effects**

Myelosuppression  
 Infertility  
 Teratogenicity  
 Hypersensitivity reactions  
 Pulmonary fibrosis  
 Electrolyte disturbances  
 Arrhythmias  
 Cardiac failure

- **Frequently occurring side effects**

Nausea and vomiting  
 Mucositis, stomatitis  
 Myelosuppression  
 Diarrhoea, constipation  
 Peripheral neuropathy  
 Oedema  
 Phlebitis  
 Myalgia, arthralgia  
 Alopecia  
 Fatigue

- **Other side effects**

Taste changes  
 Headache  
 Abdominal pain

**Significant drug interactions** – for full details consult product literature/ reference texts

**Warfarin/coumarin anticoagulants:** increased or fluctuating anticoagulant effects. Avoid if possible, consider switching patient to a low molecular weight heparin during treatment or if the patient continues taking an oral anticoagulant monitor the INR at least once a week and adjust dose accordingly.

**Clozapine:** increased risk of agranulocytosis

**Paclitaxel** is a CYP 2C8/9 and CYP 3A4 substrate. Drug levels may be increased by inhibitors of these enzymes and decreased by inducers of these enzymes.

**Additional comments**

Nil

## References

- Summary of Product Characteristics Paclitaxel (Hospira) accessed 29 October 2014 via [www.medicines.org.uk](http://www.medicines.org.uk)
- Peretz T, Sulkes A, Chollet P, Gelmon K, Paridaens R, Gorbonuva V, et al (1999) A multicenter, randomized study of two schedules of paclitaxel (PXT) in patients with advanced breast cancer.(ABC) Eur J Cancer. 31A (Supplement 5): S75.
- Verrill, M., et al –. Abstract only ASCO 2007 LBA1005

---

Written/reviewed by: Dr M Beresford (Consultant Oncologist, Royal United Hospital, Bath)

Checked by: Sarah Murdoch (Senior Oncology Pharmacist, SW Strategic Clinical Network)

Authorised by: Dr J Braybrooke (Consultant Oncologist, UHBristol NHS Trust, SW Strategic Clinical Network)

Date: 14 January 2015

---